|
|
||||||||
1Medical Biotechnological Center, University of Southern Denmark, and 2Department of Pathology, Odense University Hospital, Odense, Denmark; 3Department of Biochemistry, Medical Research Council Immunochemistry Unit, University of Oxford, Oxford, United Kingdom; 4Department of Pediatrics, University of California, Davis, California; 5Copenhagen Blood Transfusion Centre, Copenhagen University Hospital, Copenhagen, Denmark; 6Department of Pediatrics and Cardiovascular Research Institute, University of California, San Francisco, California; and 7Department of Cardiology, Aarhus University Hospital (Skejby), Aarhus, Denmark
Submitted 19 October 2005 ; accepted in final form 23 December 2005
Surfactant protein D (SP-D) is an important innate immune defense molecule that mediates clearance of pathogens and modulates the inflammatory response. Moreover, SP-D is involved in lipid homeostasis, and pulmonary accumulation of phospholipids has previously been observed in SP-D-deficient (Spd/) mice. Atherogenesis involves both inflammation and lipid deposition, and we investigated the role of SP-D in the development of atherosclerosis. SP-D synthesis was localized to vascular endothelial cells. Atherosclerotic lesion areas were 5.6-fold smaller in the aortic roots in Spd/ mice compared with wild-type C57BL/6N mice on an atherogenic diet. HDL cholesterol (HDL-C) was significantly elevated in Spd/ mice. Treatment of Spd/ mice with a recombinant fragment of human SP-D resulted in decreases of HDL-C (21%) as well as total cholesterol (26%), and LDL cholesterol (28%). Plasma TNF-
was reduced in Spd/ mice (45% difference). SP-D was proatherogenic in the mouse model used. The effect is likely to be due to the observed disturbances of plasma lipid metabolism and alteration of the inflammatory process, which underlie the reduced susceptibility to atherosclerosis in Spd/ mice.
atherosclerosis; experimental animals; high-density lipoprotein; tumor necrosis factor-
This article has been cited by other articles:
![]() |
H. Muller, M. Renner, B. M. Helmke, C. End, C. Weiss, J. Poeschl, and J. Mollenhauer Deleted in Malignant Brain Tumors 1 is up-regulated in bacterial endocarditis and binds to components of vegetations J. Thorac. Cardiovasc. Surg., September 1, 2009; 138(3): 725 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Sin, S. F. P. Man, D. D. Marciniuk, G. Ford, M. FitzGerald, E. Wong, E. York, R. R. Mainra, W. Ramesh, L. S. Melenka, et al. The Effects of Fluticasone with or without Salmeterol on Systemic Biomarkers of Inflammation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1207 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Snyder, R. E. Oberley-Deegan, K. L. Goss, S. A. Romig-Martin, L. L. Stoll, J. M. Snyder, and N. L. Weintraub Surfactant protein D is expressed and modulates inflammatory responses in human coronary artery smooth muscle cells Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2053 - H2059. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Sin, P. S. Pahlavan, and S.F. P. Man Review: Surfactant protein D: A lung specific biomarker in COPD? Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 65 - 74. [Abstract] [PDF] |
||||
![]() |
S. Hansen, B. Lo, K. Evans, P. Neophytou, U. Holmskov, and J. R. Wright Surfactant Protein D Augments Bacterial Association but Attenuates Major Histocompatibility Complex Class II Presentation of Bacterial Antigens Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 94 - 102. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |